Company news
AdAlta Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
European Patent for AD-214 granted
June 13, 2022
BIO International Convention presentation
May 31, 2022
AdAlta presentation at Bioshares Biotech Summit
May 9, 2022
Indian patent for AD-214
April 6, 2022
Inhaled AD-214 preclinical program
April 4, 2022
PAC Partners Healthcare Conference - Corporate Presentation
April 4, 2022
$1.6M Second Tranche R&D Cash Flow Loan Received
March 8, 2022
Chinese patent granted for AD-214
March 1, 2022
Change in Director Interest Notice x 4
February 10, 2022
Application for quotation of securities - 1AD
February 6, 2022
Entitlement Offer Results
February 3, 2022
Presentation to Share Cafe Webinar
January 19, 2022
Presentation Conference Schedule - January 2022
January 3, 2022
Entitlement Offer Booklet
December 22, 2021
Reinstatement to Quotation
December 14, 2021
Voluntary Suspension
December 13, 2021
Inhaled AD-214 passes first development milestone
December 8, 2021
AGM presentations & first iCAR-T data
November 28, 2021
Second US patent for AD-214
November 17, 2021
BTB funding transferred to AD-214 inhalation program
October 6, 2021
New pre-clinical data presented at Boston conference
September 26, 2021
Corporate overview and IRD Invest 2021 presentation
September 20, 2021
$4.0M Non-Dilutive Financing with Victorian Government
September 19, 2021
Carina collaboration webinar presentation
August 25, 2021
CAR-T collaboration with Carina Biotech
August 23, 2021
Webinar and presentation on AD-214 strategy
July 19, 2021
AD-214 pathway to IPF efficacy studies
July 18, 2021
AdAlta secures AD-214 resupply
July 1, 2021
R&D Tax Incentive Facility
June 24, 2021
GE Healthcare collaboration advances to next stage
May 23, 2021
AdAlta granted Japanese patent for AD-214
May 18, 2021
Mutiple Dose Part Of Ad-214 Phase I Trial Commenced
April 18, 2021
Investor briefing-AD-214 top line single dose safety results
March 9, 2021
Appendix 4D and Interim Financial Report
February 25, 2021
FDA Orphan Drug Designation for AD-214
February 23, 2021
Phase I HV extension to explore encouraging results
December 13, 2020
AGM Presentation
November 25, 2020
AusBiotech presentation including Phase I status update
October 26, 2020
Investor Presentation - BIO investor forum
October 9, 2020
GE Healthcare collaboration progresses
September 20, 2020
Non-renounceable Rights Issue Offer
August 18, 2020
Placement and Rights Offer
August 10, 2020
Investor presentation including future milestones
July 29, 2020
First participants treated in AD-214 Phase I trial
July 23, 2020
Supportive US FDA pre-IND meeting results for AD-214
July 19, 2020
AdAlta receives approval to commence AD-214 Phase I trial
June 9, 2020
Business update and COVID-19 response
March 30, 2020
Board changes and R&D Tax Incentive advance received
March 26, 2020
Investor Briefing - Strategic Plan
March 2, 2020
AD-214 effective in gold standard pre-clinical animal model
March 1, 2020
Decks
The 5 newest of 84 decks. Every deck is listed under its year.
- BIOSeedin Autumn Innovation Partnering Summit 2026
Conference · 35 slides · Sep 10, 2026
- Investor Presentation (August 2026)
Investor deck · 35 slides · Aug 13, 2026
- ISCT ANZ 2026 Regional Meeting
Conference · 14 slides · Jul 20, 2026
- Investor Presentation (April 2026)
Investor deck · 16 slides · May 11, 2026
- ANZ Biologics Festival 2026
Conference · 21 slides · Feb 4, 2026